CHM and Parkinson disease: Compared to conventional treatment, CHM paratherapy significantly improved UPDRS IV scores (WMD −0.51, 95% CI −0.83 to −0.20; Z = 3.61 (P < 0.05)), suggesting that CHM paratherapy could contribute to improving complications of treatment in patients with PD (Table 7).